Sign In
Buy SNANF
$0.211
+0.0055 (+2.68%)
At Close: Jun 02, 2026
Dow rockets higher as Strait of Hormuz stays open, talks eyed
12:23pm, Friday, 17'th Apr 2026
4:20pm: Easing tensions Markets finished the session on a strong note, with major US indexes extending their winning streak as geopolitical tensions showed...
The gas keeping the world's MRI scanners running and AI chips cool is suddenly in critically short supply. Six ASX-listed companies could find themselves in...
Dow powers higher as oil slump, easing tensions lift stocks
08:57am, Friday, 17'th Apr 2026
12:55pm: Sliding oil propels stocks "Crude futures prices fell sharply - dropping over 10% to below $86 per barrel and reaching near five-week lows - after...
Hims & Hers shares jump as FDA begins review of restricted peptide compounds
09:12am, Thursday, 16'th Apr 2026
Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration (FDA) moved to begin a formal review...
Sona Nanotech appoints two oncologists to scientific advisory board
09:00am, Thursday, 16'th Apr 2026
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the appointment of two oncologists, Michael Smylie and Jonathan Trites, to its scientific advisory board to support its ongoing clinical and re
Sona Nanotech appoints two oncologists to scientific advisory board
04:49am, Thursday, 16'th Apr 2026
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the appointment of two oncologists, Michael Smylie and Jonathan Trites, to its scientific advisory...
Sona Nanotech reports immune activation in melanoma trial of heat-based therapy
08:41am, Monday, 13'th Apr 2026
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) said tissue analysis from its first human trial of its heat-based cancer therapy showed immune system activation in late-stage melanoma patients, raising hope
Alien Metals shares jump 16% as joint ventures advance drilling at two Western Australia precious metal projects
06:11am, Wednesday, 08'th Apr 2026
Shares in Alien Metals (AIM: UFO) rose 16% to 0.12p after the company reported progress at two separate joint venture projects in the Pilbara region of...
FTSE 100 Live: Aero and defence stocks lead decline as Trump's Iran deadline looms
12:04pm, Tuesday, 07'th Apr 2026
FTSE down 82 points at 10,354 Oil and gas prices remain elevated Pres Trump set a 1am GMT deadline for Iran deal 4.03pm: Defence and aerospace stocks...
Sona Nanotech preclinical study shows tumor regression in colorectal cancer model
10:02am, Tuesday, 07'th Apr 2026
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the publication of a preclinical study examining the efficacy of its Targeted Hyperthermia Therapy (THT) in combination with immunotherapy for c
Sona Nanotech preclinical study shows tumor regression in colorectal cancer model
05:57am, Tuesday, 07'th Apr 2026
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the publication of a preclinical study examining the efficacy of its Targeted Hyperthermia Therapy...
Why precision oncology may be poised for a reset: a conversation with Sona Nanotech
12:31pm, Monday, 09'th Feb 2026
Cancer has quietly become the pharmaceutical industry's most lucrative disease area. In 2024 alone, global cancer drug sales exceeded $200 billion, making oncology the single largest revenue category
Sona Nanotech CEO on breakthrough cancer therapy results - ICYMI
02:57pm, Friday, 24'th Oct 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has reported promising first-in-human results for its targeted hyperthermia therapy (THT), showing tumor elimination in most treated patients with advanced me
Sona Nanotech poised for clinical breakthrough after melanoma study
12:54pm, Tuesday, 21'st Oct 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) is stepping into clinical-stage biotech after reporting promising results from its first-in-human trial of Targeted Hyperthermia Therapy (THT) for advanced me
Sona Nanotech reveals positive response rate in first-in-human THT cancer therapy study
08:38am, Monday, 20'th Oct 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) Inc announced that it has completed its first-in-human clinical study treating patients with histologically confirmed, immunotherapy-resistant cutaneous
